Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Haematologica ; 106(6): 1599-1607, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-32499241

RESUMEN

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010-2017. When outcomes from 2004 +/- 2009 and 2010-2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004-2009 and P <.0001 for 2010-2017), profression-free survival (P=.002 for 2004-2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers: NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.


Asunto(s)
Enfermedad Injerto contra Huésped , Neoplasias Hematológicas , Trasplante de Células Madre Hematopoyéticas , Enfermedad Injerto contra Huésped/epidemiología , Enfermedad Injerto contra Huésped/etiología , Neoplasias Hematológicas/terapia , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Acondicionamiento Pretrasplante , Donante no Emparentado
2.
N Engl J Med ; 375(10): 944-53, 2016 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-27602666

RESUMEN

BACKGROUND: The majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. Data are needed to inform the choice among various alternative donor-cell sources. METHODS: In this retrospective analysis, we compared outcomes in 582 consecutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98). RESULTS: The relative risks of death and relapse between the cord-blood group and the two other unrelated-donor groups appeared to vary according to the presence of minimal residual disease status before transplantation. Among patients with minimal residual disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazard ratio, 2.92; 95% confidence interval [CI], 1.52 to 5.63; P=0.001); the risk was also higher in the HLA-matched group than in the cord-blood group but not significantly so (hazard ratio, 1.69; 95% CI, 0.94 to 3.02; P=0.08). Among patients without minimal residual disease, the hazard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30; hazard ratio in the HLA-matched group, 0.78; 95% CI, 0.48 to 1.28; P=0.33). The risk of relapse among patients with minimal residual disease was significantly higher in the two unrelated-donor groups than in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02; hazard ratio in the HLA-matched group, 2.92; 95% CI, 1.34 to 6.35; P=0.007). Among patients without minimal residual disease, the magnitude of these associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60; hazard ratio in the HLA-matched group, 1.30; 95% CI, 0.65 to 2.58; P=0.46). CONCLUSIONS: Our data suggest that among patients with pretransplantation minimal residual disease, the probability of overall survival after receipt of a transplant from a cord-blood donor was at least as favorable as that after receipt of a transplant from an HLA-matched unrelated donor and was significantly higher than the probability after receipt of a transplant from an HLA-mismatched unrelated donor. Furthermore, the probability of relapse was lower in the cord-blood group than in either of the other groups.


Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical , Leucemia Mieloide Aguda/terapia , Síndromes Mielodisplásicos/terapia , Neoplasia Residual/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Adulto , Anciano , Niño , Preescolar , Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Femenino , Citometría de Flujo , Prueba de Histocompatibilidad , Humanos , Lactante , Masculino , Persona de Mediana Edad , Neoplasia Residual/mortalidad , Recurrencia , Estudios Retrospectivos , Análisis de Supervivencia , Trasplante Homólogo , Adulto Joven
4.
Zhonghua Xue Ye Xue Za Zhi ; 24(1): 22-4, 2003 Jan.
Artículo en Zh | MEDLINE | ID: mdl-12679005

RESUMEN

OBJECTIVE: To explore the expression of epidermal growth factor receptor (EGFR) in hematopoietic cells and investigate its relationship to apoptosis in myelodysplastic syndrome (MDS) patients. METHOD: Mononuclear cells from 18 MDS patients were used to analyze the expression of EGFR and the apoptotic signals by immunocytochemical technique and TdT-mediated dUTP nick end labelling (TUNEL) fluorescein. Flow cytometry (FCM) sorted CD(34)(+) cells from 15 MDS cases and 6 normal donors were also analyzed for the EGFR expression and apoptotic signals. Nine normal marrow samples were taken as controls. EGFR expression and its relationship to apoptosis were analysed. RESULTS: (1) There was a higher EGFR expression rate (38.6 +/- 24.6)% in nucleated cells of MDS marrow than in normal marrow (18.1 +/- 14.0)% (P < 0.05). (2) Apoptosis occurred much more in EGFR negative cells (16.1%) than in EGFR positive cells (1.4%) (P < 0.01). EGFR expression showed negative correlation with apoptosis (r = -0.701; t(r) = 3.60; P < 0.01). (3) In CD(34)(+) cells, EGFR expression rate seemed higher in RAEB/RAEB-t/CMML than that in RA/RAS (20.6 +/- 27.9 vs 8.9 +/- 11.8%) subgroup (P > 0.05), while apoptosis was lower in RAEB/RAEB-t/CMML subgroup than in RA/RAS cases (18.2 +/- 12.5 vs 45.2 +/- 20.5%) (P < 0.05). CONCLUSION: There is overexpression of EGFR in MDS cases. And it seems that the overexpressed EGFR represent somewhat the malignant proliferation in MDS and suppress apoptosis through a unknown mechanism.


Asunto(s)
Apoptosis , Receptores ErbB/biosíntesis , Síndromes Mielodisplásicos/metabolismo , Síndromes Mielodisplásicos/patología , Adulto , Anciano , Células de la Médula Ósea/metabolismo , Femenino , Citometría de Flujo , Humanos , Etiquetado Corte-Fin in Situ , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA